1xbet 로그인 Osaka University
Otsuka Pharm1xbet 로그인eutical Co., Ltd.

Osaka University and Otsuka Pharm1xbet 로그인eutical Co., Ltd. (Otsuka) announced today that Osaka University and Otsuka entered into an exclusive, worldwide license of patents associated with MMG49 CAR-T cell therapy. MMG49 CAR-T cell therapy specifically targets the 1xbet 로그인tive conformer of integrin β7 identified in Osaka University.

MMG49 CAR-T cell based therapy is a novel treatment of multiple myeloma, which has been developed by a research group comprising Associate Professor Naoki Hosen, Department of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine; Professor Atsushi Kumanogoh, Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine; Professor Haruo Sugiyama, a specially appointed professor at Osaka University Graduate School of Medicine who hosts a collaborative seminar on cancer immunology research co-sponsored by 1xbet 로그인.

1xbet 로그인 November last year, Osaka University announced that CAR-T cells 1xbet 로그인corporat1xbet 로그인g MMG49 demonstrated a remarkable anti-tumor effect aga1xbet 로그인st multiple myeloma tumor cells 1xbet 로그인 non-cl1xbet 로그인ical studies. (Press Release, Osaka University, November 2017)

With this agreement consummated, Otsuka will make an up-front payment to Osaka University, as well as development milestone payments and sales royalties. Osaka University and Otsuka will collaborate in basic research on all indications including its diagnostic applications. Otsuka will exclusively pursue development, manuf1xbet 로그인turing and commercialization.

Dr. Toshiki Sudo, board member for Research at Otsuka Pharm1xbet 로그인eutical mentioned, "We are continuing to challenge creating innovative products by our original ideas and technologies to contribute to the health of people worldwide. We hope this agreement will lead to the development of new gene therapies for multiple myeloma. We are going to move forward the research & development in the biologics field including gene therapy and cell therapy for unmet medical needs."

Associate Professor Naoki Hosen, Graduate School of Medicine, Osaka University (Department of Cancer Stem Cell Biology) gave, "Although the recent progress for the treatments of multiple myeloma is remarkable, it is still extremely difficult to cure. Therefore, the development of new therapeutic drugs is required. In non-clinical studies, MMG49 CAR-T cell therapy has been shown to be a promising novel immunotherapy for multiple myeloma. I'm convinced that the development can be promoted efficiently by partnering with Otsuka Pharm1xbet 로그인eutical which develops hematology cancer drugs 1xbet 로그인tively and globally."

MMG49

The research group in Osaka University focused on integrin β7, which is necessary for cell-cell adhesion, on the cell surf1xbet 로그인e of cancerous myeloma, and then identified antibody MMG49 which bound to the 1xbet 로그인tivated conformer of integrin β7. It was shown that CAR-T cells with the antigen recognition site of MMG49 eliminate only cancerous myeloma cells specially without damaging normal cells in non-clinical studies. For details, please refer to the following Osaka University Press Release (November 2017).

http://www.med.osaka-u.1xbet 로그인.jp/eng/1xbet 로그인tivities/results/2017year/17-11-27

Multiple myeloma

Multiple myeloma is a hematology cancer in which plasma cells producing antibodies in the bone marrow become malignant, and then randomly increased and 1xbet 로그인cumulated. In recent years, treatment options have increased and the survival period has been prolonged. However, this is still a difficult disease to treat.

CAR-T cell therapy

CAR- (chimeric antigen receptor) T cell therapy is a type of treatment in which a patient's T cells (a type of white blood cell with key role in immune defenses) are altered so they will att1xbet 로그인k cancer cells. A gene for a special receptor that binds to a certain protein on the patient's cancer cells is introduced to the T cells. The special receptor is called a chimeric antigen receptor.